Role of nonresolving inflammation in hepatocellular carcinoma development and progression.
Role of nonresolving inflammation in hepatocellular carcinoma development and progression.
复制标题
非消退性炎症在肝细胞癌发生和进展中的作用
DOI：
10.1038/s41698-018-0048-z
复制
发表时间：
2018
影响因子：
7.9
通讯作者：
Wang HY
中科院分区：
文献类型：
--
作者：
Yu LX;Ling Y;Wang HY
肝细胞癌（HCC）已成为癌症相关死亡的主要原因，因此阐明其潜在机制成为当务之急。炎症是在严格规定下对感染和组织损伤的适应性反应。当宿主调节机器失去控制时，就会发生无法解决的炎症。无法消退的炎症是公认的癌症标志，它极大地促进了 HCC 的发生和进展。 HCC 相关炎症可以通过外在途径启动和传播，通过源自肠道微生物区系的病原体相关分子模式 (PAMP) 或垂死肝细胞释放的损伤相关分子模式 (DAMP) 激活模式识别受体 (PRR)。炎症也可以由肿瘤本身通过分泌因子来精心策划，这些因子将炎症细胞招募到肿瘤，有利于微环境的建立。来自人类和小鼠模型的累积数据表明，炎症通过促进增殖和生存信号传导、诱导血管生成、逃避免疫监视、支持癌症干细胞、激活侵袭和转移以及诱导基因组不稳定来促进肝癌的发展。针对炎症可能是 HCC 治疗的一条有希望的途径。一些针对炎症途径的抑制剂已经开发出来，并处于不同阶段的临床试验中，其中一种（索拉非尼）已获得 FDA 批准。然而，由于大部分数据是从动物模型中获得的，并且人类肝癌和小鼠肝癌模型之间存在很大差异，因此从实验室到临床的成功转化具有挑战性。
Hepatocellular carcinoma (HCC) has become a leading cause of cancer-related death, making the elucidation of its underlying mechanisms an urgent priority. Inflammation is an adaptive response to infection and tissue injury under strict regulations. When the host regulatory machine runs out of control, nonresolving inflammation occurs. Nonresolving inflammation is a recognized hallmark of cancer that substantially contributes to the development and progression of HCC. The HCC-associated inflammation can be initiated and propagated by extrinsic pathways through activation of pattern-recognition receptors (PRRs) by pathogen-associated molecule patterns (PAMPs) derived from gut microflora or damage-associated molecule patterns (DAMPs) released from dying liver cells. The inflammation can also be orchestrated by the tumor itself through secreting factors that recruit inflammatory cells to the tumor favoring the buildup of a microenvironment. Accumulating datas from human and mouse models showed that inflammation promotes HCC development by promoting proliferative and survival signaling, inducing angiogenesis, evading immune surveillance, supporting cancer stem cells, activating invasion and metastasis as well as inducing genomic instability. Targeting inflammation may represent a promising avenue for the HCC treatment. Some inhibitors targeting inflammatory pathways have been developed and under different stages of clinical trials, and one (sorafenib) have been approved by FDA. However, as most of the data were obtained from animal models, and there is a big difference between human HCC and mouse HCC models, it is challenging on successful translation from bench to bedside.
登录
查看更多内容
影响因子：
30.5
作者：
Chiba, Shigeki;Baghdadi, Muhammad;Akiba, Hisaya;Yoshiyama, Hironori;Kinoshita, Ichiro;Dosaka-Akita, Hirotoshi;Fujioka, Yoichiro;Ohba, Yusuke;Gorman, Jacob V.;Colgan, John D.;Hirashima, Mitsuomi;Uede, Toshimitsu;Takaoka, Akinori;Yagita, Hideo;Jinushi, Masahisa
通讯作者：
Jinushi, Masahisa
DOI：
10.1007/978-3-0348-0837-8_16
发表时间：
2014-01-01
期刊：
INFLAMMATION AND CANCER
影响因子：
--
作者：
Bishayee, Anupam
通讯作者：
Bishayee, Anupam
影响因子：
82.9
作者：
通讯作者：
--
影响因子：
17.1
作者：
Balmer, Maria L.;Slack, Emma;Macpherson, Andrew J.
通讯作者：
Macpherson, Andrew J.
高迁移率 Group Box 1 通过 miR-21 介导的基质金属蛋白酶活性促进肝细胞癌进展。
影响因子：
11.2
作者：
Chen M;Liu Y;Varley P;Chang Y;He XX;Huang H;Tang D;Lotze MT;Lin J;Tsung A
通讯作者：
Tsung A